Lineage Cell Therapeutics (LCTX) Equity Income (2016 - 2025)
Historic Equity Income for Lineage Cell Therapeutics (LCTX) over the last 8 years, with Q3 2025 value amounting to $6000.0.
- Lineage Cell Therapeutics' Equity Income rose 20000.0% to $6000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $12000.0, marking a year-over-year increase of 14444.44%. This contributed to the annual value of -$8000.0 for FY2024, which is 9545.45% up from last year.
- Per Lineage Cell Therapeutics' latest filing, its Equity Income stood at $6000.0 for Q3 2025, which was up 20000.0% from -$2000.0 recorded in Q2 2025.
- In the past 5 years, Lineage Cell Therapeutics' Equity Income registered a high of $40000.0 during Q1 2023, and its lowest value of -$517000.0 during Q4 2022.
- For the 4-year period, Lineage Cell Therapeutics' Equity Income averaged around -$71923.1, with its median value being -$6000.0 (2023).
- Examining YoY changes over the last 5 years, Lineage Cell Therapeutics' Equity Income showed a top increase of 31666.67% in 2024 and a maximum decrease of 11250.0% in 2024.
- Quarter analysis of 4 years shows Lineage Cell Therapeutics' Equity Income stood at -$517000.0 in 2022, then soared by 98.84% to -$6000.0 in 2023, then soared by 316.67% to $13000.0 in 2024, then crashed by 53.85% to $6000.0 in 2025.
- Its Equity Income was $6000.0 in Q3 2025, compared to -$2000.0 in Q2 2025 and -$5000.0 in Q1 2025.